Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Letter to the Editor

Exploring the Possibility of Use of SARS-CoV-2 Antiserum as an Alternative for Plasma Therapy

Author(s): Basavraj Nagoba*, Ajay Gavkare and Abhijit Rayate

Volume 4, Issue 1, 2023

Published on: 11 April, 2023

Article ID: e290323215106 Pages: 3

DOI: 10.2174/2666796704666230329101950

[1]
Shen, C.; Wang, Z.; Zhao, F. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA, 2020, 323(16), 1582-1589.
[http://dx.doi.org/10.1001/jama.2020.4783] [PMID: 32219428]
[2]
Duan, K.; Liu, B.; Li, C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl. Acad. Sci. USA, 2020, 117(17), 9490-9496.
[http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
[3]
Zhang, B.; Liu, S.; Tan, T. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest, 2020, 158(1), e9-e13.
[http://dx.doi.org/10.1016/j.chest.2020.03.039] [PMID: 32243945]
[4]
Ye, M.; Fu, D.; Ren, Y. Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China. J. Med. Virol., 2020, 92(10), 1890-1901.
[http://dx.doi.org/10.1002/jmv.25882] [PMID: 32293713]
[5]
Ahn, J.Y.; Sohn, Y.; Lee, S.H. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci., 2020, 35(14), e149.
[http://dx.doi.org/10.3346/jkms.2020.35.e149] [PMID: 32281317]
[6]
Greenwood, D.; Barer, M.; Slack, R.; Irving, W. Medical Microbiology, 18th ed; London: Amsterdam: Churchill Livingstone Elsevier, 2012.
[7]
Nagoba, B.; Pichare, A. Medical Microbiology and Parasitology, 4th ed.; New Delhi: Elsevier: Amsterdam, 2020.
[8]
Cheng, Y.; Wong, R.; Soo, Y.O.Y. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24(1), 44-46.
[http://dx.doi.org/10.1007/s10096-004-1271-9] [PMID: 15616839]
[9]
Hung, I.F.N.; To, K.K.W.; Lee, C.K. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis., 2011, 52(4), 447-456.
[http://dx.doi.org/10.1093/cid/ciq106] [PMID: 21248066]
[10]
Ko, J.H.; Seok, H.; Cho, S.Y. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir. Ther., 2018, 23(7), 617-622.
[http://dx.doi.org/10.3851/IMP3243] [PMID: 29923831]
[11]
Nagoba, B.; Gavkare, A.; Jamadar, N.; Mumbre, S.; Selkar, S. Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19. J. Infect. Public Health, 2020, 13(12), 1818-1822.
[http://dx.doi.org/10.1016/j.jiph.2020.08.011] [PMID: 32900666]
[12]
Abani, O.; Abbas, A.; Abbas, F. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): A randomised controlled, open-label, platform trial. Lancet, 2021, 397(10289), 2049-2059.
[http://dx.doi.org/10.1016/S0140-6736(21)00897-7] [PMID: 34000257]
[13]
Agarwal, A.; Mukherjee, A.; Kumar, G.; Chatterjee, P.; Bhatnagar, T.; Malhotra, P. PLACID Trial Collaborators. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ, 2020, 371, m3939.
[http://dx.doi.org/10.1136/bmj.m3939] [PMID: 33093056]
[14]
Li, L.; Zhang, W.; Hu, Y. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA, 2020, 324(5), 460-470.
[http://dx.doi.org/10.1001/jama.2020.10044] [PMID: 32492084]
[15]
Gharbharan, A.; Jordans, C.C.E.; Geurtsvankessel, C. Convalescent plasma for COVID-19. A randomized clinical trial. MedRxiv, 20202020, 20139857.
[http://dx.doi.org/10.1101/2020.07.01.20139857]
[16]
Herman, A.; Fairchild, D.; Hefner, J. SARS-CoV-2 antibodies undetectable in some recovered patients. NEJM. 2020. Available from: https://www.jwatch.org/fw116548/2020/04/13/sars-cov-2-antibodies-undetectable-some-recovered?query=C19

Rights & Permissions Print Cite
Article Metrics
13
2
© 2024 Bentham Science Publishers | Privacy Policy